New US cardiology guidelines suggest cholesterol screening for children aged 9-11 to identify familial hypercholesterolemia early, preventing heart attacks and strokes in young adults.
Novartis, Amgen and Eli Lilly are in late-stage trials for drugs targeting Lp(a), a dangerous form of cholesterol affecting one in five people worldwide. Novartis expects Phase 3 results mid-2026 for pelacarsen, with Amgen and Lilly following in 2027 and 2029. The drugs have shown 80%+ Lp(a) reduction but must now prove clinical benefit. If successful, the market could reach $5.6B by 2032, though less than 1% of U.S. adults currently get tested for Lp(a).
